Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research

Stoke Therapeutics (NASDAQ:STOK) was upgraded by stock analysts at Wolfe Research to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other equities analysts have also recently weighed in on STOK. Wedbush raised their price target on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, January 12th. UBS Group set a $50.00 price objective on Stoke Therapeutics in a research note on Monday, December 15th. HC Wainwright raised their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. Guggenheim assumed coverage on Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 target price on the stock. Finally, Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and an average price target of $39.25.

Stoke Therapeutics Trading Down 2.0%

Shares of STOK stock opened at $35.50 on Monday. The firm has a fifty day simple moving average of $31.71 and a two-hundred day simple moving average of $28.05. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $38.69. The firm has a market capitalization of $2.03 billion, a PE ratio of 52.99 and a beta of 1.10.

Insider Buying and Selling

In related news, insider Barry Ticho sold 3,662 shares of Stoke Therapeutics stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $31.34, for a total value of $114,767.08. Following the completion of the sale, the insider owned 19,798 shares of the company’s stock, valued at approximately $620,469.32. This trade represents a 15.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 3,978 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $32.28, for a total transaction of $128,409.84. Following the sale, the general counsel directly owned 11,831 shares in the company, valued at approximately $381,904.68. This trade represents a 25.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 58,302 shares of company stock valued at $1,826,430. 9.50% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the business. AQR Capital Management LLC boosted its holdings in Stoke Therapeutics by 1.2% in the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after buying an additional 354 shares during the period. Strs Ohio lifted its position in shares of Stoke Therapeutics by 9.4% during the fourth quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after acquiring an additional 600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Stoke Therapeutics by 31.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the period. Generali Investments Management Co LLC boosted its holdings in shares of Stoke Therapeutics by 41.0% in the fourth quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock worth $78,000 after acquiring an additional 718 shares during the period. Finally, Kestra Advisory Services LLC purchased a new position in shares of Stoke Therapeutics in the fourth quarter valued at $26,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.